NCT Research

NCT Clinical Cancer Program in Multiple Myeloma


The Heidelberg Myeloma Program is an internationally renowned program (>6000 outpatient contacts, 169 hematopoietic stem cell transplantations in 2012). It coordinates the largest multiple myeloma study group in Germany (GMMG), which conducts international phase I-III clinical trials (Sonneveld J Clin Oncol 2012; Neben Blood 2012). Translational research projects focus on molecular risk factors (Weinhold Nature Genet 2013; Andrulis Cancer Discov 2013) and modern imaging (Hillengaß Leukemia 2013).


Scientific Goals

  • Design and conduct international multicenter clinical trials that improve high-dose therapy and new compounds that personalize myeloma treatment.
  • Development of prognostic markers to define and monitor high-risk smoldering myeloma.
  • Use novel imaging technology (DWI) to monitor bone marrow involvement and biology.

  1. Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Dührsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012; 119(4):940-8
  2. Seckinger A, Meißner T, Moreaux J, Depeweg D, Hillengass J, Hose K, Rème T, Rösen-Wolff A, Jauch A, Schnettler R, Ewerbeck V, Goldschmidt H, Klein B, Hose D. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood 2012; 120(5):1087-94
  3. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt H. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. J Clin Oncol. 2012; 30(24):2946-55
  4. Andrulis M, Lehners N, Capper D, Penzel R, Heining Ch, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS. Targeting the BRAF V600E Mutation in Multiple Myeloma. Cancer Discov. 2013; 3(8):862-869
  5. Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JA, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dörner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.